Table 2.
Characteristics of treatment exposures included in the meta-analysis
| Trial (year) | Treatment group | Treatment protocol |
|---|---|---|
| CRUISE (2010) | IVR 0.5 mg (n = 130) | IVR 0.5 mg every month for 6 months (6 injections) then PRN (open-label) for 6 months |
| IVR 0.3 mg (n = 132) | IVR 0.3 mg every month for 6 months (6 injections) then PRN (open-label) for 6 months | |
| Sham injection (n = 130) | sham injection every month for 6 months (6 injections) then PRN IVR 0.5 mg (open-label) for 6 months | |
| ROCC (2010) | IVR 0.5 mg (n = 16) | IVR 0.5 mg every month for 3 months, then as required (at the discretion of the physician) for persisting macular oedema |
| Sham injection (n = 16) | sham injection (plastic syringe pressed against the eyeball) | |
| BRAVO (2011) | IVR 0.5 mg (n = 131) | IVR 0.5 mg monthly injections then PRN (open-label) for 6 months |
| IVR 0.3 mg (n = 134) | IVR 0.3 mg monthly injections then PRN (open-label) for 6 months | |
| Sham injection (n = 132) | sham injection every month for 6 months (6 injections) then PRN IVR 0.5 mg (open-label) for 6 months | |
| Tan (2014) | IVR 0.5 mg (n = 15) | IVR 0.5 mg monthly injections up to month 5 then PRN for 6 months |
| Sham injection plus laser (n = 21) | sham injection monthly up to month 5 then PRN for 6 months, laser at week 13 and 25 if eligible |
IVR = intravitreal ranibizumab; PRN = Pro Re Nata.